With over 30 years of clinical and research experience, Dr. Georgescu is internationally recognized as Medical and Executive Director of Neuromarkers. She obtained her M.D. degree from Carol Davila Medical School, Bucharest/ Romania, M.Sc. degree in Molecular and Cellular Biology from Joseph Fourier University, Grenoble/France, and Ph.D. degree in Microbiology from Pasteur Institute, Paris/France. She has also completed a postdoctoral fellowship in Cancer Biology at the Rockefeller University, New York/ USA. Dr. Georgescu is a board-certified physician in Anatomic Pathology and Neuropathology. She is also an internationally renowned scientist, best known for her work on PI3K/PTEN signaling and cancer pathogenesis. As one of the few investigators with extensive expertise in both molecular neuro-oncology and neuropathology, she has established landmarks in brain tumor translational research and more broadly, in cancer biology. For a list of Dr. Georgescu's scientific publications, please visit: https://pubmed.ncbi.nlm.nih.gov/?term=Georgescu+MM&sort=date
Glioblastoma is a deadly brain tumor for which progress has been slow. Dr. Georgescu pioneered a breakthrough glioblastoma classification in 7 molecular subgroups, G1-G7, by combining clinical, histologic, molecular and bio-informatics approaches. This new classification permits a systematic approach to rationalized treatment and identification of targetable tumors:
https://doi.org/10.3390/cancers16020361
https://www.youtube.com/watch?v=6iQzC80CQ5k
https://doi.org/10.3390/cancers13184532
https://www.uni-muenster.de/Ejournals/index.php/fnp/article/view/5892/6271
By discovering inherited gene mutations, the genetic counseling and research at NeuroMarkers strives to explain the cause and progression of brain tumors. Studies in diffuse midline glioma (DMG) and medulloblastoma showed the necessity of molecular analysis for correct tumor diagnosis and management:
https://youtu.be/wdExv7lxiVw; https://rdcu.be/cTRDB
At NeuroMarkers, a special focus is on pediatric brain tumors, as brain cancer is the #1 cancer killer in children.
A novel diagnostic neuromarker, NHERF1/EBP50, has been developed by Dr. Georgescu and is validated for ependymoma, choroid plexus tumors, and angiocentric glioma:
Although meningioma is considered a benign brain tumor, 1 in 10 tumors will relapse. To determine which are the aggressive tumors, it is important to risk stratify the patients. Dr. Georgescu devised the first risk stratification system for chordoid meningioma:
Cerebrovascular disease ranks among the leading causes of mortality in the developed world. By performing autopsies, Dr. Georgescu described for the first time the cerebro-vascular pathology of an inherited condition that results in arteriosclerosis:
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.